Bank of New York Mellon
SPRO icon

Bank of New York Mellon’s Spero Therapeutics SPRO Stock Holding History

Bank of New York Mellon’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,966
Closed -$11K – 4598
2022
Q2 		$11K Sell
14,966
-58,104
-80% -$169K ﹤0.01% 4544
2022
Q1 		$636K Sell
73,070
-1,930
-3% -$19.8K ﹤0.01% 3570
2021
Q4 		$1.2M Buy
75,000
+793
+1% +$12.6K ﹤0.01% 3276
2021
Q3 		$1.37M Buy
74,207
+7,612
+11% +$122K ﹤0.01% 3223
2021
Q2 		$930K Buy
66,595
+3,423
+5% +$47.8K ﹤0.01% 3467
2021
Q1 		$931K Sell
63,172
-6,711
-10% -$118K ﹤0.01% 3376
2020
Q4 		$1.35M Buy
69,883
+18,357
+36% +$286K ﹤0.01% 3068
2020
Q3 		$575K Buy
51,526
+1,589
+3% +$18.8K ﹤0.01% 3421
2020
Q2 		$676K Buy
49,937
+3,873
+8% +$43.5K ﹤0.01% 3317
2020
Q1 		$371K Buy
46,064
+8,290
+22% +$73.1K ﹤0.01% 3513
2019
Q4 		$363K Buy
37,774
+551
+1% +$5.94K ﹤0.01% 3730
2019
Q3 		$395K Buy
37,223
+2,944
+9% +$31K ﹤0.01% 3676
2019
Q2 		$395K Buy
34,279
+708
+2% +$8.52K ﹤0.01% 3713
2019
Q1 		$430K Sell
33,571
-3,145
-9% -$33.4K ﹤0.01% 3619
2018
Q4 		$226K Buy
36,716
+8,888
+32% +$72K ﹤0.01% 3819
2018
Q3 		$293K Buy
27,828
+3,139
+13% +$36.4K ﹤0.01% 3832
2018
Q2 		$363K Buy
24,689
+10,490
+74% +$134K ﹤0.01% 3774
2018
Q1 		$202K Buy
+14,199
New +$172K ﹤0.01% 3930

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Bank of New York Mellon's SPRO Position: Q3 2022 in Review

Bank of New York Mellon sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 14,966 shares — an estimated $11K sold.

Bank of New York Mellon first reported a position in SPRO in Q1 2018 and held it in 18 quarters. The position peaked at $1.37M in Q3 2021. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Bank of New York Mellon reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 14,966 Spero Therapeutics shares in Q3 2022, an estimated $11K.
  • Bank of New York Mellon first reported a position in Spero Therapeutics in Q1 2018 and held it in 18 quarters.
  • Bank of New York Mellon's Spero Therapeutics position peaked at $1.37M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.